NCT06299839 - PAS-004 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2027

Conditions

RAS MutationNF1 MutationRAF MutationAdvanced Solid Tumors

Interventions

DRUG

PAS-004 Capsules

A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 1 mg, 4mg, and 10 mg strength capsules, intended for oral administration once daily.

DRUG

PAS-004 Tablets

A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 4mg strength tablets, intended for oral administration once daily.

Trial Locations (7)

1404

RECRUITING

MBAL Sveta Sofia, Sofia

22031

RECRUITING

NEXT Oncology, Fairfax

75039

RECRUITING

NEXT Oncology, Irving

78229

RECRUITING

NEXT Oncology, San Antonio

78758

ACTIVE_NOT_RECRUITING

NEXT Oncology, Austin

022328

RECRUITING

Institute of Oncology Bucharest Prof. Dr. Alexandru Trestioreanu, Bucharest

RO-400015

RECRUITING

Institute of Oncology Prof. Dr. Ion Chiricuta, Cluj-Napoca